**Synthesis of Suvorexant**

**Significance:** Orexins A and B are excitatory neuropeptides that stimulate wakefulness. Suvorexant is a dual orexin receptor antagonist that is in phase III clinical trials for the treatment of insomnia. The key step in the asymmetric synthesis depicted is a tandem enzymatic transamination–annulation sequence ($F \rightarrow G \rightarrow H$).

**Comment:** A previous synthesis of suvorexant (N. A. Strotman et al. *J. Am. Chem. Soc.* 2011, 133, 8362) involved an asymmetric Ru-catalyzed reductive amination in the construction of the diazepane ring. The present route benefits from the circumvention of transition-metal catalysis and dichloromethane as solvent.